NAMPT与恶性肿瘤的进展

doi:10.11904/j.issn.1002-3070.2016.02.014

摘要/Abstract

摘要： 烟酰胺磷酸核糖转移酶(Nicotinamide phosphoribosyltransferase,NAMPT)是烟酰胺腺嘌呤二核苷酸(Nicotinamide adenine dinucleotide,NAD)补救合成途径的关键限速酶,并参与调节细胞的代谢、增殖、凋亡等生物学过程。近年来,研究发现NAMPT在多种恶性肿瘤中表达水平升高,并与恶性肿瘤的发生、发展及治疗关系密切。NAMPT在恶性肿瘤中作用机制的研究以及NAMPT抑制剂的研究为恶性肿瘤的治疗带来了新的希望和前景。本文将NAMPT在恶性肿瘤中的研究现状做一简要综述。

关键词: NAMPT, 恶性肿瘤, 进展, 治疗

Abstract: Nicotinamide phosphoribosyltransferase(NAMPT)is the rate-limiting enzyme that catalyzes the first step in Nicotinamide adenine dinucleotide(NAD)biosynthesis and regulates biological processes such as metabolism,growth and apoptosis of cells.In the past few years,a large number of studies have found that expression level of NAMPT is increased in a variety of malignancies,which is associated with the progression and treatment of malignant tumors.The research of the mechanism of NAMPT in malignant tumors and molecule inhibitors of the NAMPT have brought new hope and prospect for the treatment of malignant tumors.This article makes a brief review of NAMPT research status in malignant tumors.

Key words: NAMPT, Nalignant tumors, Progression, Treatment

中图分类号:

李广浩综述, 张玉宝审校. NAMPT与恶性肿瘤的进展[J]. 实用肿瘤学杂志, 2016, 30(2): 158-161.

LI Guanghao, ZHANG Yubao. The research progress on NAMPT in malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 158-161.

参考文献

1 Wang T,Zhang X,Bheda P,et al.Structure of Nampt/PBEF/visfatin,a mammalian NAD+ biosynthetic enzyme[J].Nat Struct Mol Biol,2006,13(7):661-662.
2 Sethi JK.Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome[J].Curr Hypertens Rep,2007,9(1):33-38.
3 Magni G,Amici A,Emanuelli M,et al.Enzymology of NAD+ homeostasis in man[J].Cell Mol Life Sci,2004,61(1):19-34.
4 Ramsey KM,Yoshino J,Brace CS,et al.Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis[J].Science,2009,324(5927):651-654.
5 Shackelford RE,Mayhall K,Maxwell NM,et al.Nicotinamide phosphoribosyltransferase in malignancy:a review[J].Genes Cancer,2013,4(11-12):447-456.
6 Garten A,Petzold S,Korner A,et al.Nampt:linking NAD biology,metabolism and cancer[J].Trends Endocrinol Metab,2009,20(3):130-138.
7 Bi TQ,Che XM.Nampt/PBEF/visfatin and cancer[J].Cancer Biol Ther,2010,10(2):119-125.
8 孙欢,张凯,艾文兵.Nampt 在胶质瘤中的研究进展[J].实用肿瘤学杂志,2014,28(1):89-92.
9 Galli U,Travelli C,Massarotti A,et al.Medicinal chemistry of nicotinamide phosphoribosyltransferase(NAMPT)inhibitors[J].J Med Chem,2013,56(16):6279-6296.
10 Wang X,Xu TY,Liu XZ,et al.Discovery of novel inhibitors and fluorescent probe targeting NAMPT[J].Sci Rep,2015,26(5):12657-12665.
11 Hong SM,Park CW,Kim SW,et al.NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer[J].Oncogene,2015,2015:415.
12 Park HJ,Kim SR,Kim SS,et al.Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer[J].Oncotarget,2014,5(13):5087-5099.
13 Zhou T,Wang T,Garcia JG.Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers[J].Sci Rep,2014,39(4):6107-6115.
14 Yang H,Yang T,Baur JA,et al.Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival[J].Cell,2007,130(6):1095-1107.
15 Sharif T,Ahn DG,Liu RZ,et al.The NAD salvage pathway modulates cancer cell viability via p73[J].Cell Death Differ,2015,2015:134.
16 Wang B,Hasan MK,Alvarado E,et al.NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response[J].Oncogene,2011,30(8):907-921.
17 Patel ST,Mistry T,Brown JE,et al.A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis[J].Peptides,2010,31(1):51-57.
18 Dan L,Klimenkova O,Klimiankou M,et al.The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells[J].Haematologica,2012,97(4):551-559.
19 Audrito V,Serra S,Brusa D,et al.Extracellular nicotinamide phosphoribosyltransferase(NAMPT)promotes M2 macrophage polarization in chronic lymphocytic leukemia[J].Blood,2015,125(1):111-123.
20 Lv X,Zhang L,Zhu Y,et al.Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer[J].J Cancer,2015,6(9):849-858.
21 Neubauer K,Misa IB,Diakowska D,et al.Nampt/PBEF/visfatin upregulation in colorectal tumors,mirrored in normal tissue and whole blood of colorectal cancer patients,is associated with metastasis,hypoxia,IL1beta,and anemia[J].Biomed Res Int,2015,2015:523930.
22 Schuster S,Penke M,Gorski T,et al.Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes[J].PLoS One,2014,9(3):e91045.
23 Garten A,Petzold S,Barnikol-Oettler A,et al.Nicotinamide phosphoribosyltransferase(NAMPT/PBEF/visfatin)is constitutively released from human hepatocytes[J].Biochem Biophys Res Commun,2010,391(1):376-381.
24 Bauer L,Venz S,Junker H,et al.Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1[J].Int J Oncol,2009,35(1):97-107.
25 Chini CC,Guerrico AM,Nin V,et al.Targeting of NAD metabolism in pancreatic cancer cells:potential novel therapy for pancreatic tumors[J].Clin Cancer Res,2014,20(1):120-130.
26 Sawicka-Gutaj N,Waligorska-Stachura J,Andrusiewicz M,et al.Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression[J].Tumour Biol,2015,36(10):7859-7863.
27 Zhang K,Zhou B,Zhang P,et al.Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group[J].Tumour Biol,2014,35(5):4031-4040.
28 Ke HL,Lin HH,Li WM,et al.High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients[J].Am J Cancer Res,2015,5(8):2447-2454.
29 Zhao W,Chen R,Zhao M,et al.High glucose promotes gastric cancer chemoresistance in vivo and in vitro[J].Mol Med Rep,2015,12(1):843-850.
30 Zhang C,Yan D,Wang S,et al.Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma[J].BMC Gastroenterol,2015,15:49.
31 Shackelford RE,Bui MM,Coppola D,et al.Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers[J].Int J Clin Exp Pathol,2010,3(5):522-527.
32 Garten A,Schuster S,Penke M,et al.Physiological and pathophysiological roles of NAMPT and NAD metabolism[J].Nat Rev Endocrinol,2015,11(9):535-546.
33 Zhang LQ,Heruth DP,Ye SQ.Nicotinamide phosphoribosyltransferase in human diseases[J].J Bioanal Biomed,2011,28(3):13-25.
34 Hasmann M,Schemainda I.FK866,a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase,represents a novel mechanism for induction of tumor cell apoptosis[J].Cancer Res,2003,63(21):7436-7442.
35 Grozio A,Sociali G,Sturla L,et al.CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells[J].J Biol Chem,2013,288(36):25938-25949.
36 Thakur BK,Dittrich T,Chandra P,et al.Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells[J].Int J Cancer,2013,132(4):766-774.
37 Von Heideman A,Berglund A,Larsson R,et al.Safety and efficacy of NAD depleting cancer drugs:results of a phase I clinical trial of CHS 828 and overview of published data[J].Cancer Chemother Pharmacol,2010,65(6):1165-1172.
38 Hjarnaa PJ,Jonsson E,Latini S,et al.CHS 828,a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo[J].Cancer Res,1999,59(22):5751-5757.
39 Olesen UH,Christensen MK,Bjorkling F,et al.Anticancer agent CHS-828 inhibits cellular synthesis of NAD[J].Biochem Biophys Res Commun,2008,367(4):799-804.
40 Chiarugi A,Dolle C,Felici R,et al.The NAD metabolome-a key determinant of cancer cell biology[J].Nat Rev Cancer,2012,12(11):741-752.
41 Johanson V,Arvidsson Y,Kolby L,et al.Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice[J].Neuroendocrinology,2005,82(3-4):171-176.
42 Kato H,Ito E,Shi W,et al.Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma[J].Clin Cancer Res,2010,16(3):898-911.
43 Xiao Y,Elkins K,Durieux JK,et al.Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618[J].Neoplasia,2013,15(10):1151-1160.
44 Sampath D,Zabka TS,Misner DL,et al.Inhibition of nicotinamide phosphoribosyltransferase(NAMPT)as a therapeutic strategy in cancer[J].Pharmacol Ther,2015,151(6):16-31.
45 Wang W,Elkins K,Oh A,et al.Structural basis for resistance to diverse classes of NAMPT inhibitors[J].PLoS One,2014,9(10):e109366.
46 Shackelford RE,Mayhall K,Maxwell NM,et al.Nicotinamide phosphoribosyltransferase in malignancy:a review[J].Genes Cancer,2013,4(11-12):447-456.

[1]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[2]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[3]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[4]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[5]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[6]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[7]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[8]	张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.
[9]	邢志超综述, 麦威审校. 脂肪肉瘤潜在作用靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 82-86.
[10]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[11]	田洋, 吴华星. 超细鼻胃镜在消化道狭窄性疾病中的临床应用[J]. 实用肿瘤学杂志, 2018, 32(6): 550-554.
[12]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[13]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[14]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[15]	韩帮岭, 汪亦民, 薛英威. 中性粒细胞与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 349-352.